Drug Trial Radar · NCT04748796
Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility
Last checked: Nov 21, 2026Latest source record: Aug 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
360
Planned (sponsor's estimate)
Start
Feb 1, 2021
Primary completion
Jun 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Centre Hospitalier Universitaire, AmiensAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- CH Dieppe; CH Elbeuf; CH Le Havre; Centre Hospitalier de Beauvais; Centre Hospitalier Intercommunal de Compiègne-Noyon; CH Laon; University Hospital, Caen; CH Cherbourg; University Hospital, Lille; CH Douai; CH Montreuil; Centre Hospitalier de Roubaix; Centre Hospitalier de Bethune; CH Lomme; Centre Hospitalier de Lens; Tourcoing Hospital; Centre Hospitalier VALENCIENNES; Centre Hospitalier Arras; Hospital Ambroise Paré Paris; University Hospital, Brest; Henri Mondor University Hospital; Hospital Avicenne; University Hospital, Montpellier; CH Calais; Hôpital Edouard Herriot; Centre Hospitalier Universitaire de Nīmes; Groupe Hospitalier Pitie-Salpetriere; Hôpital Louis Mourier, Colombes
- First posted
- Feb 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Several data emphasize the relation between tachycardia (\>90/min) and high mortality during septic shock. The investigators previously demonstrated the high mortality associated with hypercontractility, tachycardia and the presence of a left ventricular obstruction. A severe hypovolemia, a hyper adrenergic stimulation or a severe vasoplegia can all explain this relation between tachycardia, hypercontractility and the mortality during septic shock. Landiolol is another short-term acting beta-blocker with a half-life of 4 minutes without any beta 2 activity or membrane stabilizing effect. The landiolol has been used in critically ill patients to control supraventricular tachycardia but not in this context of tachycardia and septic shock. The investigators hypothesize that landiolol by reducing the heart rate may improve the survival of patients treated for a septic shock and presenting with an hypercontractility state.
Conditions
- Septic Shock
- Tachycardia
- Mortality During Septic Shock
- Beta-blocker
Interventions
echocardiographyOther
Full echocardiography will be performed at baseline and during the follow-up at H1, H3, H6 and H12.
LandiololDrug
Patients randomized to the experimental group will be treated according to the standard of care plus for 2 days with landiolol IV started at a dose of 1 microgram/kg/min and progressively increased every 10 minutes to a maximum of 40 micrograms/kg/min.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Variation of mortality rate in landiolol group compared to control groupTime frame: day 28
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CHU Amiens
Amiens, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.